Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects.
Rossi JF, Fegueux N, Lu ZY, Legouffe E, Exbrayat C, Bozonnat MC, Navarro R, Lopez E, Quittet P, Daures JP, Rouillé V, Kanouni T, Widjenes J, Klein B. Rossi JF, et al. Among authors: fegueux n. Bone Marrow Transplant. 2005 Nov;36(9):771-9. doi: 10.1038/sj.bmt.1705138. Bone Marrow Transplant. 2005. PMID: 16113665 Free PMC article. Clinical Trial.
Mobilisation of healthy donors with lenograstim and transplantation of HLA-genoidentical blood progenitors in 54 patients with hematological malignancies: a pilot study.
Blaise D, Jourdan E, Michallet M, Jouet JP, Boiron JM, Michel G, Faucher C, Fégueux N, Schuller MP, Badri N, Chabannon C, Maraninchi D. Blaise D, et al. Among authors: fegueux n. Bone Marrow Transplant. 1998 Dec;22(12):1153-8. doi: 10.1038/sj.bmt.1701505. Bone Marrow Transplant. 1998. PMID: 9894717
Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy.
Mohty M, Fegueux N, Exbrayat C, Lu ZY, Legouffe E, Quittet P, Lopez-Martinez E, Latry P, Avinens O, Hertog C, Klein B, Eliaou JF, Rossi JF. Mohty M, et al. Among authors: fegueux n. Bone Marrow Transplant. 2001 Aug;28(4):335-9. doi: 10.1038/sj.bmt.1703134. Bone Marrow Transplant. 2001. PMID: 11571504
Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients.
Quittet P, Ceballos P, Lopez E, Lu ZY, Latry P, Becht C, Legouffe E, Fegueux N, Exbrayat C, Pouessel D, Rouillé V, Daures JP, Klein B, Rossi JF. Quittet P, et al. Among authors: fegueux n. Bone Marrow Transplant. 2006 Aug;38(4):275-84. doi: 10.1038/sj.bmt.1705441. Bone Marrow Transplant. 2006. PMID: 16883311 Free PMC article. Clinical Trial.
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC). Preudhomme C, et al. N Engl J Med. 2010 Dec 23;363(26):2511-21. doi: 10.1056/NEJMoa1004095. N Engl J Med. 2010. PMID: 21175313 Free article. Clinical Trial.
Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT.
Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Hamladji RM, Blaise D, Socié G, Lioure B, Bermudez A, Lopez-Corral L, Or R, Arcese W, Fegueux N, Nagler A, Mohty M. Kharfan-Dabaja MA, et al. Among authors: fegueux n. Bone Marrow Transplant. 2014 Sep;49(9):1170-5. doi: 10.1038/bmt.2014.133. Epub 2014 Jun 30. Bone Marrow Transplant. 2014. PMID: 24978140
118 results